Physician profile
Emily Denney
NPI 1275832057
$1,477.83
in general payments reported to CMS, 2019-2025
20 companies · $460 in 2025
The $460 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $36.33 · 2022: $14.77 · 2023: $352 · 2024: $341 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $240.01 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $219.96 | 2019-2025 | Breztri |
| Glaxosmithkline, LLC. | $184.13 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $126.93 | 2019-2023 | Vaxneuvance, M-M-R II, Gardasil 9 |
| Astellas Pharma US INC | $112.06 | 2019-2025 | Veozah |
| Amgen INC. | $105.51 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $87.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.92 | 2019-2024 | Ofev |
| Exact Sciences Corporation | $58.98 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.37 | 2025 | Caplyta |
| Corium, LLC | $31.74 | 2023-2024 | Azstarys |
| Allergan, INC. | $27.09 | 2019 | |
| Abbvie INC. | $26.87 | 2023 | Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $24.52 | 2024 | Trintellix |
| Medtronic, INC. | $22.52 | 2024 | Minimed 780g |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17.50 | 2024 | |
| Madrigal Pharmaceuticals | $15.99 | 2025 | Rezdiffra |
| Abbott Laboratories | $15.69 | 2023 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $15.50 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.28 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Denney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.